London: British drugmaker ​GSK said on Tuesday it will invest pound 400 million (USD 531 million) ​over three years in the country, including moving its R&D operations to Cambridge, as part of its plans to develop medicines faster under new CEO ‌Luke Miels. "This investment by GSK is a vote of confidence in British business. GSK's ‌decision builds on more than £3 billion in ​life sciences investment ​secured in the past 12 months under ⁠the government's Life Sciences Sector Plan, which aims to ​establish Britain among the top three life sciences ​economies by 2035. Rival AstraZeneca announced a £300 million investment in Britain earlier this year, reversing its decision to pause large-scale projects. GSK said the new 300,000-square-foot site in Cambridge, eastern England, one of Britain's leading life sciences hubs, will support research in its ‌therapeutic focus areas including cancer and respiratory diseases.